{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:26:14Z","timestamp":1780413974752,"version":"3.54.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012895","name":"Zoetis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Infestation with <jats:italic>Sarcoptes scabiei<\/jats:italic> in dogs is a debilitating disease if left untreated and is transmissible to humans. Two field studies were conducted to confirm the efficacy of orally administered sarolaner in combination with moxidectin and pyrantel (Simparica Trio<jats:sup>\u00ae<\/jats:sup>) in the treatment of sarcoptic mange in dogs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Client-owned dogs with <jats:italic>S. scabiei<\/jats:italic> infestation were enrolled and received 2 monthly treatments. In the first, small-scale study, 12 dogs each were allocated randomly to treatment with either placebo or Simparica Trio<jats:sup>\u00ae<\/jats:sup>. Skin scrapings to detect live mites and assessment of clinical signs of sarcoptic mange were conducted on Days 0, 14, 30, 44, and 60. Efficacy was calculated based on the percent reduction in arithmetic mean live mite counts relative to placebo. In the second, large-scale study, 75 dogs were allocated randomly to treatment with Simparica Trio<jats:sup>\u00ae<\/jats:sup> and 37 to treatment with afoxolaner\u2009+\u2009milbemycin oxime (NexGard Spectra<jats:sup>\u00ae<\/jats:sup>). Skin scrapings to detect live mites and assessment of clinical signs of sarcoptic mange were conducted on Days 0, 14, 30, and 60. The parasitological cure rate (percentage of dogs without live mites) was determined and non-inferiority of Simparica Trio<jats:sup>\u00ae<\/jats:sup> to the control product was assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the small-scale study, 2 monthly doses of Simparica Trio<jats:sup>\u00ae<\/jats:sup> resulted in a significant reduction (<jats:italic>P<\/jats:italic>\u2009\u2264\u20090.0050) in live <jats:italic>S.<\/jats:italic>\u00a0<jats:italic>scabiei<\/jats:italic> mite numbers and provided a 99.2% reduction relative to placebo by Day 60. Clinical signs of sarcoptic mange improved throughout the study in Simparica Trio<jats:sup>\u00ae<\/jats:sup>-treated dogs. In the large-scale study, the parasitological cure rate on Days 30 and 60 was 97.3% and 100% in the Simparica Trio<jats:sup>\u00ae<\/jats:sup> group and 91.9% and 100% in the afoxolaner\u2009+\u2009milbemycin oxime group, respectively. The parasitological cure rate for Simparica Trio<jats:sup>\u00ae<\/jats:sup> was non-inferior to afoxolaner\u2009+\u2009milbemycin oxime at both time points. Clinical signs of sarcoptic mange improved throughout the study in both groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Two-monthly doses of Simparica Trio<jats:sup>\u00ae<\/jats:sup> reduced <jats:italic>S. scabiei<\/jats:italic> mite counts by 99.2% relative to placebo in one study and eliminated <jats:italic>S. scabiei<\/jats:italic> mites in 100% of dogs in the second study, thus confirming that Simparica Trio<jats:sup>\u00ae<\/jats:sup> is highly effective in the treatment of sarcoptic mange in dogs caused by <jats:italic>S. scabiei<\/jats:italic> var. <jats:italic>canis.<\/jats:italic><\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s13071-023-06049-9","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T15:03:55Z","timestamp":1701097435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of a chewable tablet containing sarolaner, moxidectin, and pyrantel (Simparica Trio\u00ae) in the treatment of sarcoptic mange caused by Sarcoptes scabiei mite infestations in dogs"],"prefix":"10.1186","volume":"16","author":[{"given":"Csilla","family":"Becskei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Liebenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stasia","family":"Borowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"D\u2019Hanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Mahabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"6049_CR1","first-page":"1378","volume-title":"Greene\u2019s infectious diseases of the dog and cat","author":"SE Little","year":"2023","unstructured":"Little SE, Cortinas R. Mites [of dogs and cats]. In: Sykes JE, editor. Greene\u2019s infectious diseases of the dog and cat. 5th ed. Elsevier; 2023. p. 1378\u201398.","edition":"5"},{"key":"6049_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1365-3164.2004.00362.x","volume":"15","author":"CF Curtis","year":"2004","unstructured":"Curtis CF. Current trends in the treatment of Sarcoptes, Cheyletiella and Otodectes mite infestations in dogs and cats. Vet Derm. 2004;15:108\u201314.","journal-title":"Vet Derm"},{"key":"6049_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1136\/vr.148.20.621","volume":"20","author":"RS Mueller","year":"2001","unstructured":"Mueller RS, Bettenay SV, Shipstone M. Value of the pinnal-pedal reflex in the diagnosis of canine scabies. Vet Rec. 2001;20:621\u20133.","journal-title":"Vet Rec"},{"key":"6049_CR4","unstructured":"Miller WH, Griffin CE, Campbell KL, Muller GH, editors. Muller and Kirk\u2019s small animal dermatology, 7th ed. Elsevier, 2013;284\u2013342."},{"key":"6049_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.vetpar.2018.01.007","volume":"251","author":"TA Fraser","year":"2018","unstructured":"Fraser TA, Martin A, Polkinghorne A, Carver S. Comparative diagnostics reveals PCR assays on skin scrapings is the most reliable method to detect Sarcoptes scabiei infestations. Vet Parasitol. 2018;251:119\u201324.","journal-title":"Vet Parasitol"},{"key":"6049_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jvp.12959","volume":"45","author":"X Zhou","year":"2021","unstructured":"Zhou X, Hohman AE, Hsu WH. Current review of isoxazoline ectoparasiticides used in veterinary medicine. J Vet Pharmacol Ther. 2021;45:1\u201315.","journal-title":"J Vet Pharmacol Ther"},{"key":"6049_CR7","unstructured":"European Medicines Agency. Simparica\u00ae Summary of Product Characteristics. www.ema.europa.eu\/en\/documents\/product-information\/simparica-epar-product-information_en.pdf. Accessed 02 Nov 2023."},{"key":"6049_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.vetpar.2016.02.017","volume":"222","author":"C Becskei","year":"2016","unstructured":"Becskei C, De Bock F, Illambas J, Cherni J, Fourie JJ, Lane M, et al. Efficacy and safety of a novel oral isoxazoline, sarolaner (Simparica\u2122), for the treatment of sarcoptic mange in dogs. Vet Parasitol. 2016;222:56\u201361.","journal-title":"Vet Parasitol"},{"key":"6049_CR9","unstructured":"European Medicines Agency. Guideline on good clinical practice. VICH Topic GL9. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/vich-gl9-good-clinical-practices-step-7_en.pdf Accessed 02 Nov 2023."},{"key":"6049_CR10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1186\/s13071-020-04395-6","volume":"13","author":"R Chiummo","year":"2020","unstructured":"Chiummo R, Peterson I, Plehn C, Zschiesche E, Roepke R, Thomas E. Efficacy of orally and topically administered fluralaner (Bravecto\u00ae) for the treatment of client-owned dogs with sarcoptic mange under field conditions. Parasites Vectors. 2020;13:524.","journal-title":"Parasites Vectors"},{"key":"6049_CR11","unstructured":"European Medicines Agency. NexGard\u00ae Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nexgard-epar-product-information_en.pdf Accessed 02 Nov 2023."},{"key":"6049_CR12","unstructured":"European Medicines Agency. Bravecto\u00ae Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bravecto-epar-product-information_en.pdf Accessed 02 Nov 2023."},{"key":"6049_CR13","unstructured":"European Medicines Agency. NexGard Spectra\u00ae Summary of Product Characteristics. www.ema.europa.eu\/en\/documents\/product-information\/nexgard-spectra-epar-product-information_en.pdf Accessed 02 Nov 2023."},{"key":"6049_CR14","unstructured":"European Medicines Agency. Simparica Trio\u00ae Summary of Product Characteristics. https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/8847 Accessed 02 Nov 2023."}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-023-06049-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-023-06049-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-023-06049-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T03:04:23Z","timestamp":1701140663000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-023-06049-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6049"],"URL":"https:\/\/doi.org\/10.1186\/s13071-023-06049-9","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"15 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The small-scale study protocol was reviewed and approved by the laboratory\u2019s International Institutional Animal Care and Use Committee, and the large-scale study protocol was reviewed and approved by the Zoetis Ethics Review Assessment team prior to implementation. Written informed consent from each dog\u2019s owner was obtained for a dog to participate in either study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was funded by Zoetis. CB, TF, SB, LDH, and SM were employees of Zoetis. JL was a contracted Study Investigator.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"441"}}